Table 1.
Baseline characteristics in healthy control and patient cohorts
| Healthy individuals normal Lp(a) (n = 13) | Healthy individuals elevated Lp(a) (n = 12) | AKCEA-APO(a)-LRx subjects elevated Lp(a) (n = 14) | PCSK9ab subjects elevated Lp(a) (n = 18) | |
|---|---|---|---|---|
| Age (years) | 44.4 (16.8) | 44.3 (13.1) | 53.0 (7.5) | 60.6 (7.4) |
| Sex male, n (%) | 6 (46) | 6 (50) | 12 (86) | 9 (50) |
| BMI (kg/m2) | 23.6 (2.8) | 25.4 (3.3) | 29.0 (5.4) | 25.8 (3.3) |
| Smoking active, n (%) | 0 (0) | 0 (0) | 1 (7) | 2 (11) |
| SBP (mmHg) | 122 (16) | 135 (15) | 132 (15) | 135 (16) |
| DBP (mmHg) | 79 (10) | 83 (7) | 82 (7) | 82 (9) |
| CVD, n (%) | 0 (0) | 0 (0) | 14 (100) | 4 (22) |
| Coronary artery disease | 0 (0) | 0 (0) | 12 (86) | 3 (17) |
| Stroke | 0 (0) | 0 (0) | 1 (7) | 1 (6) |
| Peripheral artery disease | 0 (0) | 0 (0) | 1 (7) | 0 (0) |
| Medication use, n (%) | 0 (0) | 0 (0) | 14 (100) | 14 (78) |
| Antihypertensives | 0 (0) | 0 (0) | 11 (79) | 7 (39) |
| Antidiabetics | 0 (0) | 0 (0) | 1 (7) | 0 (0) |
| Statins | 0 (0) | 0 (0) | 12 (86) | 13 (72) |
| Ezetimibe | 0 (0) | 0 (0) | 9 (64) | 4 (22) |
| PCSK9ab | 0 (0) | 0 (0) | 2 (14) | 0 (0) |
| Total cholesterol (mmol/L)a | 5.1 (0.9) | 5.5 (0.8) | 3.8 (0.7) | 5.4 (0.9) |
| LDL-cholesterol (mmol/L)a | 3.0 (0.8) | 3.4 (0.8) | 1.9 (0.6) | 3.3 (0.7) |
| HDL-cholesterol (mmol/L)a | 1.8 (0.4) | 1.6 (0.4) | 1.2 (0.3) | 1.4 (0.4) |
| Triglycerides (mmol/L)b | 0.8 (0.3) | 1.1 (0.5) | 1.3 (0.5) | 1.4 (0.3) |
| ApoB (g/L) | 0.9 (0.2) | 1.0 (0.2) | 0.8 (0.2) | 1.0 (0.1) |
| Lipoprotein(a) (mg/dL)c | 7 (3–17) | 87 (79–114) | 82 (62–121) | 102 (64–121) |
| Leucocytes (109/L) | 5.09 (1.41) | 5.55 (0.86) | 6.60 (2.19) | 5.66 (1.63) |
| Neutrophils (109/L) | 2.56 (1.25) | 3.00 (0.44) | 3.81 (1.44) | 3.38 (1.20) |
| Lymphocytes (109/L) | 1.92 (0.60) | 1.91 (0.48) | 1.96 (0.65) | 1.66 (0.39) |
| Monocytes (109/L) | 0.39 (0.13) | 0.43 (0.12) | 0.52 (0.187 | 0.40 (0.15) |
| hs-CRP (mg/L) | 0.5 (0.3–1.8) | 1.0 (0.5–1.3) | 0.5 (0.4–2.3) | 0.9 (0.5–1.3) |
Data are represented as mean (SD), median (interquartile range), or n (%).
ApoB, apolipoprotein B; BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; Lp(a), lipoprotein(a); PCSK9ab, proprotein convertase subtilisin/kexin type 9 antibody; SBP, systolic blood pressure.
a
To convert to mg/dL, multiply by 38.7.
b
To convert to mg/dL, multiply by 88.6.
c
To convert to nmol/L, multiply by 2.5.